Managing Cancer and Living Meaningfully in Neuro-Oncology: Primary Outcomes from a Randomized Telehealth ORBIT Model Phase IIc Pilot Trial

Clicks: 14
ID: 332210
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #46 of 65 articles by views in Neuro-Oncology Practice

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Individuals with malignant brain tumors experience high rates of psychological distress, including depression and death anxiety, yet are often excluded from supportive care trials. Managing Cancer and Living Meaningfully (CALM) is a brief psychotherapy effective in advanced cancer, but untested in neuro-oncology. This randomized Phase IIc trial is the first controlled evaluation of telehealth CALM in neuro-oncology, assessing feasibility, acceptability, and clinically meaningful effects versus treatment as usual (TAU). Methods Adults with primary (grade III–IV) or secondary brain tumors and elevated depressive and/or death anxiety symptoms were randomized 2:1 to six biweekly CALM sessions or TAU. Mixed methods assessed feasibility of recruitment and data collection, acceptability, and clinically meaningful symptom change. Results Of 105 patients screened, 66% were eligible, 87% consented (N = 60), and 58 were randomized (CALM n = 39; TAU n = 19), supporting feasibility. Among CALM participants, 77% completed treatment, 90% reported high benefit, and all would recommend it. Depressive symptoms decreased in both groups (CALM d = −0.51; TAU d = −0.53). Greater effects were observed for death anxiety (CALM d = −0.95; TAU d = −1.03), with more CALM participants achieving meaningful (63%) and sustained reductions (52%) versus TAU (46% and 25%). Participants reported positive experiences with CALM and telehealth, supporting scalability in neuro-oncology care. Minor improvements were recommended in the study procedures. Conclusions Telehealth CALM is feasible, acceptable, and shows signal for meaningful benefit, particularly for reducing death anxiety, a core yet under-targeted distress domain in malignant brain cancer. Findings address a major gap and support progression to a fully powered Phase III efficacy trial.
Reference Key
openalex_W7221701964 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ashlee R. Loughan, Autumn Lanoye, Gary Rodin, Leroy Thacker, Alexandria Davies, Christopher Kleva, Amber Fox, Giuliana Zarrella, Suzanne Mazzeo, Mary Bridgman, Max Hernand, Karly Derrigo, Dace S. Svikis
Are you one of these authors? Claim your profile
Journal Neuro-Oncology Practice
Year 2026
DOI
10.1093/nop/npag096
URL
https://doi.org/10.1093/nop/npag096
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.